For laboratory research use only · Not for human or veterinary use · 18+
Metabolic research

Buy Mazdutide Peptide in Australia

Lyophilised powder, 10mg vial · Available to order, dispatched from Australia
$294.99

Buy Mazdutide in Australia from Macropus Peptides as a priced 10mg research vial, ready to order. Mazdutide is a lipidated peptide modelled on oxyntomodulin, a natural gut hormone, and it activates both the GLP-1 receptor and the glucagon receptor from one molecule, without the GIP receptor activity found in dual and triple incretin agonists. That receptor pair makes it a useful comparator in studies that separate the glucagon contribution from the incretin one. The vial holds lyophilised powder under a crimped seal, labelled with compound, strength, lot number and storage temperature, and a certificate of analysis is issued for every lot. Order online, add bacteriostatic water to the same order, and the parcel ships from local Australian stock to any Australian address. Mazdutide is supplied to adults aged 18 and over for in-vitro laboratory research only, not for human or veterinary use.

1
Frequently bought together
For in-vitro laboratory research only. Not for human or veterinary use. Purchasers must be 18 or over.
CompoundMazdutide
Amount10 mg
FormLyophilised powder
CategoryMetabolic research
Storage-20 °C, protect from light
TestingHPLC purity 98% or higher and mass spectrometry identity, every batch
Certificate of analysisAvailable for every lot, matched to the lot number on the label
Peptide calculator

Mazdutide 10mg vial

Enter the diluent volume added to this vial to see the solution concentration. Laboratory calculation only, not dosing guidance.

Vial content
10 mg
mg per mL5.00
mcg per mL5,000

Buy Mazdutide Australia: 10mg Research Vial

Macropus Peptides supplies this GLP-1 and glucagon receptor dual agonist in a single strength, a 10mg lyophilised vial held on Australian shelves and ready for checkout. It is the oxyntomodulin-based agonist that incretin laboratories use to study the glucagon arm without GIP activity, and every vial is lot-released from a single managed source with its own certificate.

Mazdutide Australia: what the peptide is

Mazdutide, known in development as LY3305677 and later as IBI362, is a synthetic peptide built on the pattern of oxyntomodulin. Oxyntomodulin is a 37 amino acid fragment of proglucagon that intestinal L cells release together with GLP-1, and it weakly activates both the GLP-1 and glucagon receptors. Because natural oxyntomodulin disappears from circulation in minutes, the synthetic version carries substitutions that resist peptidases plus an albumin-binding fatty acid, stretching activity to around a week. It has completed phase 3 trials, which makes it one of the more mature glucagon-containing agonists available as research material. In 2025 it became the first GLP-1 and glucagon dual agonist to gain approval as a medicine anywhere, in China, while in Australia it remains unregistered research material.

The parent hormone explains the design. Oxyntomodulin is the full 29 residue glucagon sequence followed by an eight residue extension, KRNRNNIA, and that tail is what gives it a foothold at both receptors. The synthetic analogue keeps the dual activity but trades the fragile native chain for one built to last in circulation.

Mazdutide peptide: how GLP-1 and glucagon signals combine in research

The GLP-1 receptor sits on pancreatic beta cells and on neurons that regulate appetite, and it amplifies glucose-dependent insulin release. The glucagon receptor is concentrated in the liver, where it controls glucose output, amino acid turnover and the oxidation of fatty acids. A peptide that engages both at once lets researchers test what the hepatic glucagon arm adds on top of incretin signalling. Because this molecule has no GIP receptor activity, it fills a specific gap in comparator panels: set beside a GLP-1-only agonist, Tirzepatide for GIP plus GLP-1, and Retatrutide for all three, it isolates the glucagon contribution cleanly. In cell work both arms are read out through cyclic AMP in lines carrying one receptor at a time, and the GLP-1 receptor antagonist exendin 9-39 can switch off one side so the glucagon response is seen alone.

Mazdutide research: what the published studies show

The human record began with a phase 1b multiple ascending study in EClinicalMedicine in 2021, which measured safety, tolerability and pharmacokinetics in Chinese adults. A randomised phase 2 study followed in Nature Communications in 2023, then phase 3 results in NEJM in 2025 covering cardiometabolic markers and safety. All three were run in China, and the preclinical receptor data came from the discovery programme behind them. Most receptor potency data still come from that discovery programme rather than independent groups, so laboratories often confirm activity in house against a reference agonist before a large panel. Designs and measurements are summarised in our Mazdutide research studies library.

Mazdutide vial specifications

SpecificationDetail
CompoundMazdutide
Amount10 mg
FormLyophilised powder
CategoryMetabolic research
Storage-20 °C, protect from light

A white lyophilised plug fills the base of the vial beneath a crimped seal. Printing on the glass identifies the oxyntomodulin analogue, its 10mg content, a lot code and the freezer temperature. We pair that lot code with its certificate on request, and the unopened vial is kept at -20 °C with light excluded.

Mazdutide price per mg for Australian labs

StrengthPricePrice per mg
Mazdutide 10mg$294.99$29.50 per mg

One strength means one unit cost: the Australian dollar figure in the table, divided by ten, is what each milligram of the oxyntomodulin analogue costs. The Survodutide vial is priced within a few dollars of it, so a head-to-head study of the two GLP-1 and glucagon agonists costs almost the same on each arm. Per milligram it sits above our Tirzepatide and Retatrutide vials, a gap worth budgeting for when one panel carries all three agonists, although every vial is filled, sealed and lot-tested the same way. Buy the full number of vials for a comparison in one order so the whole series stays on a single lot.

Mazdutide 10mg: the one vial size we stock

Ten milligrams covers receptor activation assays, a comparator arm in an incretin panel, or method development on one lot. Groups running it head to head with Survodutide can reconstitute both 10mg vials the same way so pipetting volumes match across arms. Stock strengths for this vial:

  • 2 mL added: 5 mg per mL
  • 4 mL added: 2.5 mg per mL
  • 5 mL added: 2 mg per mL

For longer panels, split the fresh stock into single-use tubes on mixing day so the lipidated chain is not warmed and chilled repeatedly. At 5 mg per mL, a 50 microlitre tube holds 250 micrograms, so one 2 mL stock fills forty such tubes; at 2 mg per mL the same tube carries 100 micrograms, which suits the lower end of a concentration response curve.

Best place to buy Mazdutide Australia

  • Sold online at macropuspeptides.com, priced at $294.99
  • Every batch HPLC tested to 98% or higher purity, with identity confirmed by mass spectrometry
  • A certificate of analysis for every lot, matched to the lot number printed on the label
  • Same-day dispatch from Australian stock for orders paid before 2pm AEST on a business day
  • Tracked delivery Australia wide: standard in 2 to 5 working days, express in 1 to 2 working days
  • Payment by PayID or bank transfer, with your order ID as the reference

How to get Mazdutide: ordering online

  • Select the 10mg vial and choose a quantity
  • Add it to the cart with any comparator peptides
  • Name bacteriostatic water on the order if required
  • Finish checkout as an adult research purchaser
  • Keep the lot code and ask for the certificate

Mazdutide calculator: working out bac water volumes

Type a diluent volume into the calculator on the listing and it returns the resulting Mazdutide concentration, in milligram and microgram units. Handy figures:

  • 1 mL: 10 mg per mL
  • 2 mL: 5 mg per mL
  • 5 mL: 2 mg per mL

Agitation can clump lipidated chains like this one, so let bacteriostatic water slide down the vial wall and turn it slowly between the fingers. More diluents are listed in lab supplies.

Is Mazdutide available in Australia

Only as a research peptide. The oxyntomodulin analogue is absent from the ARTG and unapproved by the TGA; supplying it for human or animal use is off limits, and our sales cover in-vitro benchwork only. Research peptides fall under the Poisons Standard, which the TGA amends periodically, so establish the current position for your organisation first.

Mazdutide for sale Australia wide: delivery to every state

Vials leave our Australian facility for Melbourne, Brisbane, Perth, Adelaide, Hobart, Canberra, Darwin and regional research sites, cushioned upright with the closure protected. No overseas leg means no customs hold on a temperature-sensitive lipidated peptide. It is most often ordered with Survodutide, the other GLP-1 and glucagon dual agonist we carry, and with Cagrilintide for amylin work. Browse the full metabolic research range.

References

  1. IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple ascending dose phase 1b study. EClinicalMedicine. 2021.
  2. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nature Communications. 2023.
  3. Once-weekly mazdutide in Chinese adults with obesity or overweight. New England Journal of Medicine. 2025.

Scientific content compiled from the peer-reviewed literature above by the Macropus Peptides technical team. Information is provided for research reference only.

Questions about Mazdutide 10mg

Chat on WhatsApp
Mazdutide 10mg$294.99